Lymphomatous meningitis: Incidence, prognosis and treatment

American Journal of Cancer

Volumn 1, Issue 6, 2002, Pages 423-434

  Chamberlain, Marc C ^a   Nolan, Craig P ^b   Abrey, Lauren E ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CYTARABINE; DEPO CYT; DIAZIQUONE; GADOLINIUM; INTERFERON; INTERLEUKIN 2; MAFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; THIOTEPA;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID FLOW; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; HUMAN; INCIDENCE; LYMPHOMA; LYMPHOMATOUS MENINGITIS; MENINGITIS; MYELOGRAPHY; NERVE FIBER; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL;

EID: 0042820258     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201060-00005     Document Type: Review

References (80)

1. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38: 245-52
2. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9: 225-9
3. van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999; 53: 382-5
4. Freedman A, Nadler LM. Non-Hodgkin's lymphomas. In: Holland J, Bast Jr RC, Morton ML, ET AL., editors. Cancer medicine. 4th ed. Baltimore (MD): Williams & Wilkins, 1997: 2757-95
5. Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17: 2479-85
6. Recht L, Straus DJ, Cirrincione C, et al. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988; 84: 425-35
7. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin's lymphoma: a single-center study of 532 patients. Arch Neurol 1997; 54: 854-9
8. Ersboll J, Schultz HB, Thomsen BL, et al. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985; 35: 487-96
9. Litam JP, Cabanillas F, Smith TL, et al. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood 1979; 54: 1249-57
10. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8: 141-5
11. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998: 91: 1178-84
12. Chamberlain MC, Kormanik PA. Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 1997; 49: 1728-31
13. Chamberlain M. Leptomeningeal metastases. In: Levin V. editor. Cancer in the nervous system. New York: Churchill Livingstone. 1996: 282-90
14. Murray J, Greco F, Wolff S, et al. Neoplastic meningitis: marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983; 75: 289-94
15. Wasserstrom W, Glass J, Posner J. Diagnosis and treatment of leptomeningeal metastases from solid tumors experience with 90 patients. Cancer 1982; 49: 759-72
16. Jeffery GM, Frampton CM, Legge HM, et al. Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990; 22: 20-3
17. Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996; 77: 543-8
18. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25 (2): 103-19
19. Wasserstrom WR, Schwartz MK, Fleisher M, et al. Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Sci 1981; 11 (3): 239-51
20. Van Zanten AP, Twijnstra A, Hart AA, et al. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta 1986; 161 (3): 259-68
21. Klee GG, Tallman RD, Goellner JR., et al. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986; 61 (1): 9-13
22. Twijnstra A, van Zanten AP, Hart AA, et al. Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurg Psychiatry 1987; 50 (3): 313-20
23. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, et al. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neuro Oncol 1989; 7 (1): 57-63
24. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000; 54 (8): 1670-6
25. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50 (4): 1173-5
26. Garson JA, Coakham HB, Kemshead JT, et al. The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 1985; 3 (2): 165-71
27. Hovestadt A, Henzen-Logmans SC, Vecht CJ. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 1990; 62 (4): 653-4
28. Boogerd W, Vroom TM, van Heerde P, et al. CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 1988; 51 (1): 142-5
29. van Oostenbrugge RJ, Hopman AH, Ramaekers FC, et al. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 1998; 38 (2-3): 127-33
30. Cibas ES, Malkin MG, Posner JB, et al. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987; 88 (5): 570-7
31. Biesterfeld S, Bernhard B, Bamborschke S, et al. DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluid. Acta Neuropathol (Berl) 1993; 86 (5): 428-32
32. Van Oostenbrugge RJ, Hopman AH, Arends JW, et al. The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 1998; 51 (3): 906-8
33. Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996; 77 (3): 543-8
34. Cheng TM, O'Neill BP, Scheithauer BW, et al. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994; 34 (4): 590-5
35. Glass J, Melamed M, Chernik N, et al. Malignant cells in cerebrospinal fluid (CSF) the meaning of a positive csf cytology. Neurology 1979; 29: 1369-75
36. Chamberlain M, Sandy A, Press G. Leptomeningeal metastasis a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40: 435-8
37. Gomori JM, Heching N, Siegal T. Leptomeningeal metastases: evaluation by gadolinium enhanced spinal magnetic resonance imaging. J Neurooncol 1998; 36: 55-60
38. Sze G, Soletsky S, Bronen R, et al. MR Imaging of the cranial meninges with emphasis on contrast enhancements and meningeal carcinomatosis. AJNR Am J Neuroradiol 1989; 10: 965-75
39. Collie DA, Sellar RJ, Steyn JP, et al. The diagnostic yield of magnetic resonance imaging (MRI) of the brain and spine requested by general practitioners: comparison with hospital clinicians. Br J Gen Pract 1999; 49: 559-61
40. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995; 23: 233-8
41. Kim K, Ho S, Weinberg P, et al. Spinal leptomeningeal infiltration by systemic cancer myelographic features. AJR Am J Roentgenol 1982; 139: 361-5
42. Kramer E, Rafto S, Packer R, et al. Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in children. Neurology 1991; 41: 46-50
43. Chamberlain M, Corey-Bloom J. Leptomeningeal metastases indium-DTPA CSF flow studies. Neurology 1991; 41: 1765-9
44. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998; 37: 271-84
45. Paulus JA, Bos GM, Lowenberg B, et al. Treatment results and the prognosis in patients with localization of non-Hodgkin's-lymphoma in the central nervous system. Ned Tijdschr Geneeskd 1998 Oct 3; 142: 2196-200
46. Yoshida S, Morii K, Watanabe M, et al. Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 2000; 53: 163-7
47. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997; 54: 1364-8
48. Blasberg R, Patlak C, Fenstermacher J. Intrathecal chemotherapy brain tissue profiles after ventriculo-cisternal perfusion. J Pharmacol Exp Ther 1975; 195: 73-83
49. Magrath IT, Haddy TB, Adde MA. Treatment of patients with high-grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? Leuk Lymphoma 1996; 21: 99-105
50. Balis F, Poplack D. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989; 11: 74-86
51. Collins J. Pharmacokinetics of intraventricular administration. J Neurooncol 1983; 1: 283-91
52. Bokstein F, Lossos A, Lossos IS, et al. Central nervous system relapse of systemic non-Hodgkins lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002; 43: 587-93
53. Siegal T, Lassos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463-9
54. Boogerd W, Hart AAM, Van dec Sande F, et al. Meningeal carcinomatosis breast cancer: prognostic factors and influence of treatment. Cancer 1991; 67: 1685-95
55. Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma. Cancer 1996; 77 (7): 1315-23
56. Chamberlain MC. Kormanik P, Glantz M. Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol Rep 1998; 5:521-3
57. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5
58. Williams CD, Pearce R, Taghipour G, et al. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome: a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994; 12: 2415-22
59. Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 352-8
60. Giannone L, Greco F, Hainsworth J. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986; 4: 68-73
61. Hitchens R, Bell D, Woods R, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-62
62. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993; 11: 561-9
63. Shapiro W, Young D, Mehta B. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161-6
64. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-6
65. Chamberlain MC, Kormanik PA. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694-9
66. Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994 Nov 16; 86: 1711-6
67. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 3325-30
68. Taiwo BO. AIDS-related primary CNS lymphoma: a brief review. AIDS Read 2000; 10: 486-91
69. DeAngelis LM, Wong E, Rosenblum M, et al. Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer 1992; 70: 1607-11
70. Desai J, Mitnick RJ, Henry DH, et al. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. Cancer 1999; 86: 1840-7
71. Balmaceda C, Gaynor JJ, Sun M, et al. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995; 38: 202-9
72. Goldstein JD, Dickson DW, Moser FG, et al. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathologic study with results of treatment with radiation. Cancer 1991; 67: 2756-65
73. Raez LE, Patel P, Feun L, et al. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS) -related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998; 9: 199-208
74. Chamberlain MC, Kormanik PA. AIDS-related central nervous system lymphomas. J Neurooncol 1999; 43: 269-76
75. Chamberlain M, Dirr L. Involved field radiotherapy and intra-ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 1993; 11: 1978-84
76. Chamberlain MC, Kormanik PA. Prognostic significance of co-existent bulky metastatic CNS disease in patients with leptomeningeal metastases. Arch Neurol 1997; 54: 1364-8
77. Chamberlain MC, Kormanik P. Prognostic significance of indium-DTPA CSF flow studies. Neurology 1996; 46 (6): 1674-7
78. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-50
79. Herrilinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary CNS lymphoma. Ann Neurol 2002; 51: 247-52
80. Fisher BJ, Sieferheld W, Schultz C, et al. Secondary analysis of RTOG 9310: an intergroup phase 11 combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 2001; 51 (3) Suppl. 1: 166-77